Registry for Autoimmune Interstitial Lung Disease
Official title: Characteristics of Patients With Autoimmune Interstitial Lund Disease From Argentina
Run by EPIMAR registry · NCT05365009 · Data updated 2026-11-12
This study is collecting information from people with autoimmune interstitial lung disease to see how the disease affects them and how different treatments work over five years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | EPIMAR registry Research network |
| Locations | 1 site (Buenos Aires) |
| Status | Recruiting |
| Started | April 10, 2022 |
| Main results expected | April 2023 |
| Study ends | October 2027 |
| Registry record updated | May 6, 2022 |
| Trial ID | NCT05365009 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this registry are adults aged 18 and older who have been diagnosed with interstitial lung disease related to autoimmune conditions within the last five years.
✕Probably not a fit
Patients who do not have a confirmed diagnosis of interstitial lung disease or those unable to participate in follow-up assessments may not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to collect and analyze data from patients diagnosed with autoimmune interstitial lung disease (Ai-ILD) over a five-year period. It will document various characteristics including sociodemographic, clinical, serological, functional, and radiological data, as well as treatment patterns and outcomes. The study will also investigate the frequency of subclinical Ai-ILD, risk factors for disease progression, and the safety and efficacy of different treatment approaches. By employing a multidisciplinary approach, the registry seeks to enhance understanding and management of Ai-ILD.
Why it matters
Potential benefit: If successful, this registry could lead to improved diagnosis, treatment strategies, and overall management of patients with autoimmune interstitial lung disease.
How similar studies have gone: While there have been studies on interstitial lung diseases, this registry approach focusing specifically on autoimmune-related cases is relatively novel and aims to fill existing gaps in knowledge.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old * Diagnosis of ILD within the last 5 years according to the criteria of the multidisciplinary team composed of at least one pulmonologist and one rheumatologist, with or without respiratory symptoms. * ILD defined by the presence of ground glass opacities and / or peribronchovascular or airspace consolidations and / or reticulations and / or traction bronchiectasis and / or honeycomb on high-resolution computed tomography (HRCT) within the last 12 months 17 . * One of the following three criteria (see annex 1): Established or early stage CTD 18-30. IPAF according to ATS / ERS 2015 classification criteria 8 ANCA positivity by immunofluorescence confirmed by ELISA, with or without systemic vasculitis 31. * Spirometry performed within the last 6 months before entering the registry. * The participant must sign the informed consent voluntarily. Exclusion Criteria: * Not being able to perform the clinical follow-up or the complementary studies required in the protocol. * Not being able to be evaluated by a multidisciplinary team; at least a rheumatologist plus a pulmonologist. * ILD associated with another non-autoimmune etiology according to the criteria of the multidisciplinary team (eg, occupational diseases, toxic)
Where it's running
-
Epimar Ii
Buenos Aires, Argentina Recruiting
Study contacts
- Principal investigator: Florencia Vivero, MD — Sociedad Argentina Reumatologia
- Study coordinator: Florencia Vivero, MD
- Email: florenciavivero82@gmail.com
- Phone: 542236184381
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Western Sweden Systemic Sclerosis Project
This project will collect blood, skin and DNA samples from people with systemic sclerosis in Western Sweden to try to find genes, proteins, and immune changes linked to how the disease starts and gets worse.
-
Testing new treatments for lung disease caused by scleroderma
This study is testing new treatments for lung disease caused by scleroderma to see if they can improve lung function in adults with this condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.